Study of the Vascular Effects of Serelaxin

Coronary Artery Disease Clinical Trial

Official title:

A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-controlled Study to Evaluate the Effects of Intravenous Serelaxin Infusion on Micro- and Macrovascular Function in Patients With Coronary Artery Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01979614
• Other study ID #: CRLX030A2203
• Secondary ID: 2012-001945-42
• Status: Completed
• Phase: Phase 2
• Start date: February 3, 2014
• Est. completion date: August 17, 2016

Study information

• Verified date: April 2019
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This was a mechanistic study in patients with coronary artery disease on the effects of Serelaxin on micro- and macrovascular function.

Description:

double blind, randomized, parallel group, placebo controlled study

Recruitment information / eligibility

• Status: Completed
• Enrollment: 58
• Est. completion date: August 17, 2016
• Est. primary completion date: August 17, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male and female patients =18 years of age, with body weight <160 kg.

• Patients with proven obstructive coronary artery disease, determined either by functional (e.g. treadmill testing) or non-invasive clinical imaging assessments (e.g. stress-echo, PET or SPECT myocardial perfusion), or invasive coronary angiography or by CT coronary angiography at any point in time in patients with or without mild left ventricular systolic dysfunction (LVSD)

Exclusion Criteria:

• Previous treatment with serelaxin (also known as: RLX030, relaxin)

• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of study treatment.

• Current or planned dialysis.

• Impaired renal function during screening defined as an estimated glomerular filtration rate (eGFR) at screening and prior to treatment of <30 mL/min/1.73 m2, calculated using the simplified Modification of Diet in Renal Disease (sMDRD) equation due to potential issue with administration of GdDTPA used as the MRI contrast agent.

• Sick-Sinus-Syndrome

• Current or history of pulmonary edema, including suspected sepsis.

• restrictive, or constrictive cardiomyopathy (does not include restrictive mitral filling patterns seen on Doppler echocardiographic assessments of diastolic function)

• Known significant valvular disease (including any of the following: severe aortic stenosis [AVA < 1.0 or peak gradient > 50 on prior or current echocardiogram], severe aortic regurgitation, or severe mitral stenosis).

• Clinical diagnosis of acute coronary syndrome (ACS) including unstable angina within 30 days prior to screening as determined by both clinical and enzymatic criteria

• Troponin elevation and dynamics indicative of ACS at any time between screening and randomization.

• Previous myocardial infarction within 3 months of screening

• History of Coronary Artery Bypass Graft (CABG) surgery

• Heart failure due to significant arrhythmias (including any of the following:

ventricular tachycardia, bradyarrhythmias with ventricular rate < 45 beats per minute or any second or third degree AV block or atrial fibrillation/flutter with ventricular response of > 120 beats per minute)

• Any surgical or medical condition which in the opinion of the investigator may place the patient at higher risk from his/her participation in the study (e.g., history of poor tolerance of adenosine or 3 vessel coronary disease)

• Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (does not include restrictive mitral filling patterns seen on Doppler echocardiographic assessments of diastolic function).

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Drug:
• Serelaxin
Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution

Other:
• Placebo
5% v/v glucose solution

Locations

Country	Name	City	State
United Kingdom	Novartis Investigative Site	Clydebank	West Dumbartonshire
United Kingdom	Novartis Investigative Site	Edinburgh
United Kingdom	Novartis Investigative Site	Leicester

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Statistical Analysis of Change From Baseline to Day 3 in Myocardial Perfusion Endpoints Compared With Mid Perfusion Reserve Index Using ANCOVA End Points	Global MPRI (Myocardial Perfusion Reserve Index) is defined as ratio between mean global myocardial blood flow values at rest and during adenosine stress with Mid Perfusion Reserve Index or Midl PRI (Mid Perfusion Reserve Index) which is defined as ratio between mid myocardial blood flow values at rest and during adenosine stress	baseline to Day 3
Secondary	Change From Baseline in Aortic Distensibility Measured by MRI	Measurements of arterial stiffness from cardiac MRI - Mean (SD) [n]; Aortic distensibility was assessed by MRI and pulse wave velocity using the SphygmoCor device.; (mmHg-1)	At pre-dose on Day 1 (baseline) until Day 180 after the start of drug infusion
Secondary	Change From Baseline in Aortic Velocity	Summary table for measurements of arterial velocity from cardiac MRI - Mean (SD) [n]; Aortic distensibility was assessed by MRI and pulse wave velocity using the SphygmoCor device	At pre-dose on Day 1 (baseline) until Day 180 after the start of drug infusion
Secondary	Change From Baseline in Augmentation Index Measured From Sphygmocor Device	Summary of values and change from baseline in augmentation index by time and treatment; The change from baseline in Augmentation Index was analyzed using a repeated measures analysis of covariance including treatment, time, treatment by time, baseline by time interactions and baseline as fixed factors with an unstructured variance-covariance matrixStatistical analysis of change from baseline in augmentation index using repeated measures Analysis of Covariance	Day1, Day 2, Day 3, Day 30 and Day 180 after the start of infusion
Secondary	Statistical Analysis of Change From Baseline in Augmentation Index Using Repeated Measures Analysis of Covariance	The change from baseline in Augmentation Index was analyzed using a repeated measures analysis of covariance including treatment, time, treatment by time, baseline by time interactions and baseline as fixed factors with an unstructured variance-covariance matrixStatistical analysis of change from baseline in augmentation index using repeated measures Analysis of Covariance; For analysis of change from baseline, only subjects with results at both baseline and post-baseline could be included; The augmentation index is a ratio calculated from the blood pressure waveform, it is a measure of wave reflection and arterial stiffness. Augmentation index is commonly accepted as a measure of the enhancement (augmentation) of central aortic pressure by a reflected pulse wave	Day1, Day 2, Day 3, Day 30 and Day 180 after the start of infusion
Secondary	Change From Baseline in Pulse Wave Velocity Measured From Carotid-femoral Pulse Wave Analysis	Pulse wave velocity was assessed by the SphygmoCor device	Day1, Day 2, Day 3, Day 30 and Day 180 after the start of infusion
Secondary	Serum Concentration of Serelaxin	Summary statistics of serelaxin serum PK concentrations; Blood samples were taken to measure serelaxin concentration	Day1, Day 2, Day 3 and Day 30 after the start of infusion
Secondary	Serum Concentration of Antibodies to Serelaxin	Frequency and percentage of anti-Serelaxin antibodies; Blood samples were taken to measure antibodies to serelaxin concentration at Pre-dose on Day 1, and at Day 30 after the start of the 48h drug infusion	From pre-dose on Day 1 until Day 30 after the start of drug infusion
Secondary	Systemic Clearance of Serelaxin	Systemic clearance was estimated using the rate of serelaxin infusion and the steady state concentration	From pre-dose on Day 1 until 48h after the start of drug infusion